These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 6480148)

  • 1. Radiation absorbed dose estimates at the cellular level for some electron-emitting radionuclides for radioimmunotherapy.
    Jungerman JA; Yu KH; Zanelli CI
    Int J Appl Radiat Isot; 1984 Sep; 35(9):883-8. PubMed ID: 6480148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetric aspects of radiolabeled antibodies for tumor therapy.
    Humm JL
    J Nucl Med; 1986 Sep; 27(9):1490-7. PubMed ID: 3528417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends.
    Steiner M; Neri D
    Clin Cancer Res; 2011 Oct; 17(20):6406-16. PubMed ID: 22003068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies.
    Wessels BW; Rogus RD
    Med Phys; 1984; 11(5):638-45. PubMed ID: 6503879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-based cancer treatment with ultra-short range Auger electron-emitting radionuclides: dual receptor and DNA targeting strategies.
    Karagiannis TC
    Hell J Nucl Med; 2007; 10(3):155-9. PubMed ID: 18084655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fundamentals of radioimmunotherapy.
    Eary JF
    Int J Rad Appl Instrum B; 1991; 18(1):105-8. PubMed ID: 2010294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioimmunotherapy with alpha-particle emitting radionuclides.
    Zalutsky MR; Pozzi OR
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiolabelled monoclonal antibodies in oncology. III. Radioimmunotherapy.
    Britton KE; Mather SJ; Granowska M
    Nucl Med Commun; 1991 Apr; 12(4):333-47. PubMed ID: 2067740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Technological advances in radioimmunotherapy.
    Dearling JL; Pedley RB
    Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):457-69. PubMed ID: 17537620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calculation of radiation doses for nonuniformity distributed beta and gamma radionuclides in soft tissue.
    Kwok CS; Prestwich WV; Wilson BC
    Med Phys; 1985; 12(4):405-12. PubMed ID: 4033585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-dose-fractionation in radioimmunotherapy: implications for selecting radionuclides.
    Rao DV; Howell RW
    J Nucl Med; 1993 Oct; 34(10):1801-10. PubMed ID: 8410301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
    Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
    Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy of solid tumors: from fairytale to reality.
    Adams GP; Weiner LM
    Cancer Biother Radiopharm; 2001 Feb; 16(1):9-11. PubMed ID: 11279802
    [No Abstract]   [Full Text] [Related]  

  • 14. Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting α-particles or Auger electrons.
    Aghevlian S; Boyle AJ; Reilly RM
    Adv Drug Deliv Rev; 2017 Jan; 109():102-118. PubMed ID: 26705852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monte Carlo single-cell dosimetry of Auger-electron emitting radionuclides.
    Bousis C; Emfietzoglou D; Hadjidoukas P; Nikjoo H
    Phys Med Biol; 2010 May; 55(9):2555-72. PubMed ID: 20393237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosimetry of Auger-electron-emitting radionuclides: report no. 3 of AAPM Nuclear Medicine Task Group No. 6.
    Humm JL; Howell RW; Rao DV
    Med Phys; 1994 Dec; 21(12):1901-15. PubMed ID: 7700197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Principles of radioimmunotherapy for hematologists and oncologists.
    Press OW; Rasey J
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):62-73. PubMed ID: 11226002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.
    Kawashima H
    ScientificWorldJournal; 2014; 2014():492061. PubMed ID: 25379535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A model-based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selection.
    Flynn AA; Green AJ; Pedley RB; Boxer GM; Dearling J; Watson R; Boden R; Begent RH
    Cancer; 2002 Feb; 94(4 Suppl):1249-57. PubMed ID: 11877753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.